Abstract:Objective: To summarize the pharmacology of the calcitonin peptide family of receptors and explore their relationship to migraine and current migraine therapies. Background: Therapeutics that dampen calcitonin gene-related peptide (CGRP) signaling are now in clinical use to prevent or treat migraine. However, CGRP belongs to a broader peptide family, including the peptides amylin and adrenomedullin. Receptors for this family are complex, displaying overlapping pharmacologic profiles. Despite the focus on CGRP and the CGRP receptor in migraine research, recent evidence implicates related peptides and receptors in migraine. Methods: This narrative review summarizes literature encompassing the current pharmacologic understanding of the calcitonin peptide family, and the evidence that links specific members of this family to migraine and migraine-like behaviors. Results: Recent work links amylin and adrenomedullin to migraine-like behavior in rodent models and migraine-like attacks in individuals with migraine. We collate novel information that suggests females may be more sensitive to amylin and CGRP in the context of migraine-like behaviors. We report that drugs designed to antagonize the canonical CGRP receptor also antagonize a second CGRP-responsive receptor and speculate as to whether this influences therapeutic efficacy. We also discuss the specificity of current drugs with regards to CGRP isoforms and how this may influence therapeutic profiles. Lastly, we emphasize that receptors related to, but distinct from, the canonical CGRP receptor may represent underappreciated and novel drug targets. Conclusion: Multiple peptides within the calcitonin family have been linked to migraine. The current focus on CGRP and its canonical receptor may be obscuring pathways to further therapeutics. Drug discovery schemes that take a wider view of the receptor family may lead to the development of new anti-migraine drugs with favorable clinical profiles. We also propose that understanding these related peptides and receptors may improve our interpretation regarding the mechanism of action of current drugs.

Developments in targeting calcitonin gene-related peptide

CGRP Modulating Therapies: An Update

CGRP as the target of new migraine therapies — successful translation from bench to clinic

Calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraine

Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class

A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene-related peptide and beyond

Beyond CGRP: The calcitonin peptide family as targets for migraine and pain

Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine—Clinical Considerations

Understanding the efficacy and tolerability of migraine treatment: a deep dive into CGRP antagonists

Preventive CGRP-targeted therapies for chronic migraine with and without medication-overuse headache

TEV-48125: a Review of a Monoclonal CGRP Antibody in Development for the Preventive Treatment of Migraine

Inflammatory complications of CGRP monoclonal antibodies: a case series

Targeting CGRP via receptor antagonism and antibody neutralisation in two distinct rodent models of migraine-like pain

Potential benefits and possible risks of CGRP-targeted multitherapy in migraine

Migraine therapeutics differentially modulate the CGRP pathway

Novel Calcitonin Gene-Related Peptide (CGRP) Interfering Migraine Therapies and Stroke—A Review

From CGRP to PACAP, VIP, and Beyond: Unraveling the Next Chapters in Migraine Treatment

CGRP therapy in primary care for migraine: prevention and acute medication

Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine

Calcitonin gene-related peptide inhibitors in the treatment of migraine in the pediatric and adolescent populations: a review